Black Diamond Therapeutic... (BDTX)
Company Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors.
It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations.
The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations.
It has a strategic partnership with OpenEye Scientific Software, Inc.
The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018.
Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Jan 31, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Dr. Mark A. Velleca M.D., Ph.D. |
Contact Details
Address: One Main Street Cambridge, Massachusetts United States | |
| Website | https://www.blackdiamondtherapeutics.com |
Stock Details
| Ticker Symbol | BDTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001701541 |
| CUSIP Number | 09203E105 |
| ISIN Number | US09203E1055 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark A. Velleca M.D., Ph.D. | Chief Executive Officer, President & Chairman |
| Brent Hatzis-Schoch Esq., J.D. | Chief Operating Officer & General Counsel |
| Elizabeth L. Montgomery | Chief People Officer |
| Dr. David M. Epstein Ph.D. | Co-Founder & Director |
| Dr. Elizabeth Buck Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer |
| Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVice President of Finance & Corporate Controller |
| Melanie Morrison | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 31, 2025 | 4 | Filing |
| Jan 31, 2025 | 4 | Filing |
| Jan 31, 2025 | 4 | Filing |
| Jan 31, 2025 | 4 | Filing |
| Jan 31, 2025 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |